Frequency of Different Ligament Tears in Knee Injury On Magnetic Resonance Imaging

Background: MRI had been useful in the diagnosis of ligament injuries and the tears were detected by non-invasive procedure. Objective: To determine the frequency of different ligament tears in knee injury on Magnetic Resonance Imaging. Methods: A descriptive cross-sectional was conducted with the sample size of 206 patients of both genders by selecting the convenient sampling from Ghurki Trust Teaching Hospital, Lahore. Out of 206 patients, 157 were males while 49 were females. Data was analyzed with the help of SPSS version 24. The results were derived by mean, frequency and standard deviation. Results: Findings shows that among 206 patients, with in age limit of 12 years to 70 years. 157(76.2%) were males and 49(23.7%) were female while 96(46.6%) were presented with ACL tear, 19(9.2%) were presented with PCL tears, 51(25.7%) were presented with MCL tears, 33(16.0%) patients were presented with LCL tears and all of these 206 patients were suffering from pain. Conclusion: We concluded that males are more prevalent than females and in this population the incidence of ACL tears is more than other ligament tears. Hence, ACL is proved to be the most injured ligament. Keywords: Anterior cruciate ligament, Posterior cruciate ligament, Medial collateral ligament, Lateral collateral ligament and Magnetic resonance imaging. DOI: 10.7176/JHMN/71-06 Publication date: February 29th 202

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

Background: Tranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding. Methods: We did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124. Findings: Between July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98). Interpretation: We found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial

Genome Based Research in Aquaculture

Genome -based technologies are being instigated to manipulate the structure and function of the genome and to identify the genes of interest for genetic modification of economically important species. Genome editing technologies have also been designed for genetic manipulation of aquaculture species to increase production and quality with minimum investment costs. DNA marker technologies are the most widely used genome technologies. DNA fingerprints are used to construct physical maps while genetic maps are based upon meiotic recombination. BAC fingerprinting is the commonly used method for physical mapping. Next- generation sequencers revolutionized science and allowed the de-novo whole genome sequencing. QTL mapping has made it possible to identify the genes responsible for a particular trait. Government involvement and better training of aqualturists are direly needed to reinforce the practical implications of genome- based technologies

Influence of wastewater irrigation on soil chemical properties and buildup of heavy metals in soil

The contamination of soil and plants by heavy metals is one of the crucial issues to be faced in the world including Pakistan and requires attention because heavy metals above their normal ranges are highly threatened to both plants and animals. To monitor this situation, a survey study was conducted to diagnose the concentration of toxic metals and other chemical properties of wastewater irrigated soils. For this purpose, soil samples were collected from various districts of Punjab, Pakistan and analyzed for heavy metals (cadmium, lead, chromium, nickel) and chemical properties such as electric conductivity, pH, organic matter and macronutrients (Nitrogen, Phosphorus, Potassium and Sodium contents). Result showed that pH of wastewater irrigated surface soil was alkaline in nature. Results also revealed that use of wastewater irrigation improved the O.M content (upto 2%) in soils. Macronutrient dynamics also increased specially build up in total N up to 0.12%, Olsen P (45 mg kg-1), Extractable K and Na (608, 1525 mg kg-1 respectively) was also observed in soils of wastewater irrigated areas. Furthermore, results also indicated that the concentration of heavy metal, cadmium was ranged from 0.004-3.44 mg kg-1, lead 0.05-279.3 mg kg-1, chromium 0.004-683 mg kg-1 and nickel 0.01-221.7 mg kg-1 in wastewater irrigated areas of Punjab. It was observed that, 28, 19, 15 and 5% samples were found above the permissible limits (35, 100, 0.8 and 85 mg kg-1) of Ni, Cr, Cd and Pb, respectively. Based on the results, the order of heavy metal contamination in the wastewater irrigated soil of Punjab occurred as Ni>Cr>Cd>Pb. This study concluded that untreated wastewater affect chemical properties of soil as well as degrades soil quality and at the same time it’s continues use ultimately responsible for buildup of heavy metals in soils.    

Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial

BackgroundTranexamic acid reduces surgical bleeding and reduces death due to bleeding in patients with trauma. Meta-analyses of small trials show that tranexamic acid might decrease deaths from gastrointestinal bleeding. We aimed to assess the effects of tranexamic acid in patients with gastrointestinal bleeding.MethodsWe did an international, multicentre, randomised, placebo-controlled trial in 164 hospitals in 15 countries. Patients were enrolled if the responsible clinician was uncertain whether to use tranexamic acid, were aged above the minimum age considered an adult in their country (either aged 16 years and older or aged 18 years and older), and had significant (defined as at risk of bleeding to death) upper or lower gastrointestinal bleeding. Patients were randomly assigned by selection of a numbered treatment pack from a box containing eight packs that were identical apart from the pack number. Patients received either a loading dose of 1 g tranexamic acid, which was added to 100 mL infusion bag of 0·9% sodium chloride and infused by slow intravenous injection over 10 min, followed by a maintenance dose of 3 g tranexamic acid added to 1 L of any isotonic intravenous solution and infused at 125 mg/h for 24 h, or placebo (sodium chloride 0·9%). Patients, caregivers, and those assessing outcomes were masked to allocation. The primary outcome was death due to bleeding within 5 days of randomisation; analysis excluded patients who received neither dose of the allocated treatment and those for whom outcome data on death were unavailable. This trial was registered with Current Controlled Trials, ISRCTN11225767, and ClinicalTrials.gov, NCT01658124.FindingsBetween July 4, 2013, and June 21, 2019, we randomly allocated 12 009 patients to receive tranexamic acid (5994, 49·9%) or matching placebo (6015, 50·1%), of whom 11 952 (99·5%) received the first dose of the allocated treatment. Death due to bleeding within 5 days of randomisation occurred in 222 (4%) of 5956 patients in the tranexamic acid group and in 226 (4%) of 5981 patients in the placebo group (risk ratio [RR] 0·99, 95% CI 0·82–1·18). Arterial thromboembolic events (myocardial infarction or stroke) were similar in the tranexamic acid group and placebo group (42 [0·7%] of 5952 vs 46 [0·8%] of 5977; 0·92; 0·60 to 1·39). Venous thromboembolic events (deep vein thrombosis or pulmonary embolism) were higher in tranexamic acid group than in the placebo group (48 [0·8%] of 5952 vs 26 [0·4%] of 5977; RR 1·85; 95% CI 1·15 to 2·98).InterpretationWe found that tranexamic acid did not reduce death from gastrointestinal bleeding. On the basis of our results, tranexamic acid should not be used for the treatment of gastrointestinal bleeding outside the context of a randomised trial.</div